Pre-Halt Valuation (rNPV)
$3.85B
Baseline asset value (Phase 3 CVD)
Impaired Asset Value
$0.42B
-89.1% total impairment writedown
Cumulative Approval Odds
11.2%
Shifted from 65.0% base probability
Freed R&D Capital Pool
+$320M
Unspent budget ready for redeployment
rNPV Impairment Waterfall & Capital Bridge
Impact of DSMB terminations on gross asset valuation (USD Billions)
Click trial cards on the right to toggle halted vs. active status and model counterfactuals.
Clinical Portfolio Attrition Status
Click to toggle trial termination or re-activation
Pipeline Impairment Valuation Assumptions & Reallocation
Adjust core financial parameters to test salvage valuations and redeployment yield
9.5%
Pharma industry weighted average cost of capital (WACC)
18.0%
Refractory monotherapy or biomarker-defined subgroup
$45M
Monitoring close-out, patient safety follow-up, and site audits
1.4x
Expected value creation multiple when redirected into GLP-1/GIP combos
Asset Level Accounting & DSMB Telemetry Audit
Granular trial metrics and terminal impairment categorization
| Trial ID | Protocol Description | Phase | Enrolled Patients | Primary Endpoint | DSMB Threshold Trigger | Unspent Capital | Status |
|---|